170097-82-2

Basic information

• Product Name: Carbonic acid, (benzoyloxy)methyl 4-nitrophenyl ester
• CAS NO: 170097-82-2
• Molecular Formula: C15H11NO7
• Molecular Weight: 317.255
• Mol File: 170097-82-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Carbonic acid, (benzoyloxy)methyl 4-nitrophenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, (benzoyloxy)methyl 4-nitrophenyl ester(170097-82-2)
• EPA Substance Registry System: Carbonic acid, (benzoyloxy)methyl 4-nitrophenyl ester(170097-82-2)

Safety Data

• Hazardous Substances Data: 170097-82-2(Hazardous Substances Data)

Upstream product

• 583-15-3 mercury(II) benzoate 
• 50780-50-2 4-chloromethoxycarbonyloxy-1-nitrobenzene 
• 100-02-7 4-nitro-phenol 
• 101623-71-6 iodomethyl(4-nitrophenyl)carbonate 
• 65-85-0 benzoic acid 

Downstream Products

• 1541195-71-4 (2S,3S,4R)-2-(benzoyloxymethoxycarbonylamino)-1-O-α-D-galactopyranosyl-4-hexacosanoyloctadecane-1,3,4-triol 
• 393078-36-9 (S)-3-[N-(benzoyloxymethyleneoxycarbonyl)aminomethyl]-5-methylhexanoic acid 

Relevant articles and documents

MEROPENEM DERIVATIVES AND USES THEREOF

The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection).

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.

Mono and bis double ester prodrugs of novel aminomethyl-THF 1β-methylcarbapenems

Mono and bis double ester prodrugs of aminomethyl THF 1β-methylcarbapenems 1 were Mono double ester derivatives (2, 4 and 7) did not demonstrate significantly improved oral activity due to the presence of the charged species. However, bis double ester derivatives (3 and 5) demonstrated enhanced oral activity.